Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash from Operations (2019 - 2026)

Pliant Therapeutics has reported Cash from Operations over the past 8 years, most recently at 19229000.0 for Q1 2026.

  • Quarterly Cash from Operations rose 60.65% to 19229000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 98701000.0 through Mar 2026, up 43.31% year-over-year, with the annual reading at 128336000.0 for FY2025, 17.47% up from the prior year.
  • Cash from Operations was 19229000.0 for Q1 2026 at Pliant Therapeutics, down from 17788000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 17788000.0 in Q4 2025 and troughed at 48864000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 30271000.0 (2024), against an average of 30238823.53.
  • Year-over-year, Cash from Operations crashed 95.83% in 2023 and then soared 62.68% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 31239000.0 in 2022, then grew by 19.65% to 25102000.0 in 2023, then crashed by 89.87% to 47662000.0 in 2024, then soared by 62.68% to 17788000.0 in 2025, then dropped by 8.1% to 19229000.0 in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Cash from Operations are 19229000.0 (Q1 2026), 17788000.0 (Q4 2025), and 21081000.0 (Q3 2025).